How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

PAX-5 – the most sensitive and reliable biomarker for B-cell malignancies

Organization name

Max-Planck-Innovation GmbH

Profile

Background

Pax-5, or B-cell-specific activator protein, is a nuclear protein in the paired-box containing (PAX) family of transcription factors involved
in control of organ development and tissue differentiation.
Pax-5 staining is positive in most Hodgkin and B-cell non-Hodgkin lymphomas and also precursor B-cell lymphoblastic neoplasms. Plasma cell neoplasms, multiple myeloma and plasmablastic lymphomas, as well as T-cell lymphomas, are typically negative.
Pax-5 immunohistochemistry therefore has become a well accepted and valuable tool in diagnosis and subclassification of lymphomas.

Technology

MPG possesses and provides intellectual property rights to the use of Pax-5 directed probes, encompassing Pax(-5)-directed nucleic acid probes as well as anti-Pax-5-antibodies, as tumor-diagnostics. The IP was developed at the Max Planck Institute of biophysical chemistry in Göttingen by Prof. Gruss and co-workers.

Patent Information

US patent 5,747,250 was granted on May 5th 1998.
EP patent 0655926 was granted on Jan 28th 1998.

Competitiveness of Pax-5 based diagnostics in the field:

  • most sensitive and reliable diagnostic biomarker to date
  • background-free nuclear immunoreactivity achievable
  • superior maintenance of expression over established B-cell markers (CD19, CD20, CD79a or alike)
  • well suited to monitor patients post-rituximab treatment to unanimously detect CD20-negative B-cell lymphomas

Licenses available:

The Pax-5 related intellectual property of Max Planck Society is available preferably for non-exclusive licensing.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries